Wcn24-2099 Baseline Characteristics of the Align Trial: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Atrasentan in Patients With Igan

Endothelin A (ETA) receptor activation drives proteinuria, kidney inflammation and fibrosis in IgA nephropathy (IgAN). Atrasentan, a potent and selective ETA receptor antagonist, is a potential therapy to reduce proteinuria and preserve kidney function in patients with IgAN. Interim results from the IgAN cohort of the open-label AFFINITY study demonstrated atrasentan was well tolerated and resulted in clinically meaningful proteinuria reductions at 12 and 24 weeks. The ongoing ALIGN study (NCT04573478) is a global, phase 3, randomized, double-blind, placebo-controlled clinical trial of atrasentan in patients with IgAN at high risk of kidney function loss.